TARX (Tarsier Pharma) Inventories, Raw Materials & Components: $0.00 Mil (As of Dec. 2025)


What is Tarsier Pharma Inventories, Raw Materials & Components?

Tarsier Pharma TARX Inventories, Raw Materials & Components is $0.00 Mil as of Dec. 2025.

Tarsier Pharma's inventories, raw materials & components for the quarter that ended in Dec. 2025 was $0.00 Mil.

Tarsier Pharma Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Inventories, Raw Materials & Components Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Raw Materials & Components 0.00 0.00 0.00 0.00 0.00

Tarsier Pharma Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?
Tarsier Pharma (TARX) has a Inventories, Raw Materials & Components of $0.00 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Inventories, Raw Materials & Components too high?
Tarsier Pharma's current Inventories, Raw Materials & Components is $0.00 Mil.
How does Tarsier Pharma's Inventories, Raw Materials & Components compare to ?
Tarsier Pharma's Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Inventories, Raw Materials & Components of $0.00 Mil. The current Inventories, Raw Materials & Components is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Inventories, Raw Materials & Components is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.